Fulcrum Therapeutics, Inc.

FULC: Is Fulcrum Therapeutics, Inc. Halal?

Fulcrum Therapeutics, Inc.

NASDAQHealthcareUS

$3.70

+0.54%

Market Cap: 200.2M

Compliance Status

Not Halal

Screened on Sep 1, 2026 · AAOIFI Standard 21

F

Non-Compliant

0Score

Is Fulcrum Therapeutics, Inc. (FULC) halal? Not Halal. Based on AAOIFI screening, Fulcrum Therapeutics, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Quote this verdict

HalalScreener rates Fulcrum Therapeutics, Inc. (FULC) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Sep 1, 2026. Source: https://halalscreener.app/en/stock/FULC

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

2.2% of 30.0% limit

What this means for you

Most scholars advise not holding FULC

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Sep 1, 2026

Compliance History

  1. Not Halalnow

    since Aug 2026

  2. Under Review

    until the change above

  3. Halal

    until the change above

Tracked since Jun 2026. Updates automatically on each re-screen.

Fiscal: FY 2025Data source: FMP
Free · No credit card required

Track FULC and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Fulcrum Therapeutics, Inc. (FULC) halal to invest in?
Fulcrum Therapeutics, Inc. (FULC) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.
Why did Fulcrum Therapeutics, Inc. get a F compliance rating?
Fulcrum Therapeutics, Inc. (FULC) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 2.2% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Fulcrum Therapeutics, Inc.'s Shariah verdict?
Fulcrum Therapeutics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Fulcrum Therapeutics, Inc. re-screened for Shariah compliance?
Fulcrum Therapeutics, Inc. (FULC) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Sep 1, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.